Aquestive Therapeutics, Inc. (AQST) stock
AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.78+0.08 (+2.16%)
Close on Nov 18, 2026Market cap $474.43MP/E –Yield –
Aquestive Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Aquestive Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$52.75M. For fiscal 2025 it was -$71.05M. The highest annual figure on record is -$113.00K in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$71.05M | – |
| FY2024 | Dec 31, 2024 | -$30.77M | – |
| FY2023 | Dec 31, 2023 | -$15.10M | – |
| FY2022 | Dec 31, 2022 | -$42.07M | – |
| FY2021 | Dec 31, 2021 | -$34.68M | – |
| FY2020 | Dec 31, 2020 | -$42.89M | – |
| FY2019 | Dec 31, 2019 | -$52.67M | – |
| FY2018 | Dec 31, 2018 | -$48.93M | – |
| FY2017 | Dec 31, 2017 | -$113.00K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$8.22M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.20M | – |
| Q4 FY2025 | Dec 31, 2025 | -$28.84M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.48M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.37M | -20769.1% |
| Q1 FY2025 | Mar 31, 2025 | -$19.37M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.58M | – |
| Q3 FY2024 | Sep 30, 2024 | -$8.29M | – |
| Q2 FY2024 | Jun 30, 2024 | $55.00K | – |
| Q1 FY2024 | Mar 31, 2024 | -$8.96M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.91M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.38M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.21M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.61M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.71M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.85M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.76M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.74M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.67M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.97M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.52M | -1749.9% |
| Q1 FY2021 | Mar 31, 2021 | -$8.53M | – |
| Q4 FY2020 | Dec 31, 2020 | -$15.65M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.78M | – |
| Q2 FY2020 | Jun 30, 2020 | $395.00K | – |
| Q1 FY2020 | Mar 31, 2020 | -$13.86M | – |
| Q4 FY2019 | Dec 31, 2019 | -$9.90M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.00M | -307.4% |
| Q2 FY2019 | Jun 30, 2019 | -$18.69M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.07M | -225.5% |
| Q4 FY2018 | Dec 31, 2018 | -$12.35M | – |
| Q1 FY2018 | Mar 31, 2018 | $5.31M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.26M | – |
| Q3 FY2017 | Sep 30, 2017 | $10.42M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.06M | – |
See a number that looks wrong?